Articoli di riviste: "Targeted nanotherapy"

1

Kim, Gloria J., e Shuming Nie. "Targeted cancer nanotherapy". Materials Today 8, n. 8 (agosto 2005): 28–33. http://dx.doi.org/10.1016/s1369-7021(05)71034-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Mathew, Anila, Toru Maekawa e D. Sakthikumar. "Aptamers in Targeted Nanotherapy". Current Topics in Medicinal Chemistry 15, n. 12 (17 aprile 2015): 1102–14. http://dx.doi.org/10.2174/1568026615666150413153525.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Zhu, Peng, Carl Atkinson, Suraj Dixit, Qi Cheng, Danh Tran, Kunal Patel, Yu-Lin Jiang et al. "Organ preservation with targeted rapamycin nanoparticles: a pre-treatment strategy preventing chronic rejection in vivo". RSC Advances 8, n. 46 (2018): 25909–19. http://dx.doi.org/10.1039/c8ra01555d.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

(a) Rapamycin nanotherapeutic pre-treatment improves tracheal allograft outcome after transplantation. (b) Nanotherapy reduces aortic allograft vasculopathy. (c) Dose dependency of the nanotherapy in aortic interposition allografts.

4

Crintea, Andreea, Anne-Marie Constantin, Alexandru C. Motofelea, Carmen-Bianca Crivii, Maria A. Velescu, Răzvan L. Coșeriu, Tamás Ilyés, Alexandra M. Crăciun e Ciprian N. Silaghi. "Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer". Journal of Functional Biomaterials 14, n. 9 (9 settembre 2023): 466. http://dx.doi.org/10.3390/jfb14090466.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advances in treatment, the prognosis remains poor, highlighting the need for novel therapeutic strategies. The present review explores the potential of targeted epidermal growth factor receptor (EGFR) nanotherapy as an alternative treatment for NSCLC, showing that EGFR-targeted nanoparticles are efficiently taken up by NSCLC cells, leading to a significant reduction in tumor growth in mouse models. Consequently, we suggest that targeted EGFR nanotherapy could be an innovative treatment strategy for NSCLC; however, further studies are needed to optimize the nanoparticles and evaluate their safety and efficacy in clinical settings and human trials.

5

Narayanan, Sreeja, N. S. Binulal, Ullas Mony, Koyakutty Manzoor, Shantikumar Nair e Deepthy Menon. "Folate targeted polymeric ‘green’ nanotherapy for cancer". Nanotechnology 21, n. 28 (28 giugno 2010): 285107. http://dx.doi.org/10.1088/0957-4484/21/28/285107.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Katsogiannou, M., L. Peng, C. V. Catapano e P. Rocchi. "Active-Targeted Nanotherapy Strategies for Prostate Cancer". Current Cancer Drug Targets 11, n. 8 (1 ottobre 2011): 954–65. http://dx.doi.org/10.2174/156800911797264770.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Metcalfe, Su M., e Tarek M. Fahmy. "Targeted nanotherapy for induction of therapeutic immune responses". Trends in Molecular Medicine 18, n. 2 (febbraio 2012): 72–80. http://dx.doi.org/10.1016/j.molmed.2011.11.002.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Hu, Xiankang, e Jianxiang Zhang. "Yeast capsules for targeted delivery: the future of nanotherapy?" Nanomedicine 12, n. 9 (maggio 2017): 955–57. http://dx.doi.org/10.2217/nnm-2017-0059.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Rapoport, N. Ya, K. H. Nam, Z. Gao e A. Kennedy. "Application of ultrasound for targeted nanotherapy of malignant tumors". Acoustical Physics 55, n. 4-5 (18 luglio 2009): 594–601. http://dx.doi.org/10.1134/s1063771009040162.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Soodgupta, Deepti, Dipanjan Pan, Grace Hu, Angana Senpan, Xiaoxia Yang, Katherine N. Weilbaecher, Edward V. Prochownik, Gregory M. Lanza e Michael H. Tomasson. "Preclinical Development Of a Nanomedicne Approach For Multiple Myeloma Targeting The Myc Oncoprotein". Blood 122, n. 21 (15 novembre 2013): 4228. http://dx.doi.org/10.1182/blood.v122.21.4228.4228.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract Purpose This study investigated alpha 4 beta 1/ Very Late Antigen-4 (α4β1/ VLA-4)-integrin targeted nanotherapy approach to deliver a new lipase-labile prodrug. Experimental Design A phospholipid-based MYC-MAX inhibitor prodrug (MI1-PD) was synthesized, and its inherent anti-proliferate potency was compared to the lipid-free compound (MI1) using mouse multiple myeloma (MM) cell line (5TGM1). VLA-4-targeted perfluorocarbon (PFC) nanoparticles binding to 5TGM1 cells was measured and compared to biomarker expression assessed with flow cytometry using antibodies. The efficacy of MI1-PD incorporated into non-targeted and VLA-4-targeted PFC NP exposed to 5TGM1 cells was assessed with MTT assays, Annexin V and cell cycle analysis. Results MI1-PD was more potent by several orders of magnitude than its free drug counterpart in culture. Targeted NP binding correlated well with biomarker expression assessment by flow cytometry in 5TGM1 cells. Non-targeted NPs had no appreciable binding to 5TGM1 cells. High anti-MM potency of MI1-PD was noted in VLA-4-targeted NPs compared to the non-targeted NPs demonstrating that the efficacy was dependent on expression of the targeted biomarker to afford particle-to-cell drug delivery. Conclusions These results suggest the feasibility of an improved integrin VLA-4- targeted nanotherapy approach to deliver a lipase- labile prodrug construct, MI1-PD. Disclosures: No relevant conflicts of interest to declare.

11

Koneru, Tejaswi, Eva McCord, Shreya Pawar, Katyayani Tatiparti, Samaresh Sau e Arun K. Iyer. "Transferrin: Biology and Use in Receptor-Targeted Nanotherapy of Gliomas". ACS Omega 6, n. 13 (22 marzo 2021): 8727–33. http://dx.doi.org/10.1021/acsomega.0c05848.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Keen, Judith C. "A step towards a new targeted nanotherapy for pancreatic cancer". Cancer Biology & Therapy 7, n. 10 (ottobre 2008): 1591–92. http://dx.doi.org/10.4161/cbt.7.10.6758.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Zhou, Xia-Qing, Ya-Ping Li e Shuang-Suo Dang. "Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy". World Journal of Hepatology 16, n. 2 (27 febbraio 2024): 164–76. http://dx.doi.org/10.4254/wjh.v16.i2.164.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a major challenge to global health due to its high morbidity and mortality. Conventional chemotherapy is usually targeted to patients with intermediate to advanced stages, but it is often ineffective and suffers from problems such as multidrug resistance, rapid drug clearance, nonspecific targeting, high side effects, and low drug accumulation in tumor cells. In response to these limitations, recent advances in nanoparticle-mediated targeted drug delivery technologies have emerged as breakthrough approaches for the treatment of HCC. This review focuses on recent advances in nanoparticle-based targeted drug delivery systems, with special attention to various receptors overexpressed on HCC cells. These receptors are key to enhancing the specificity and efficacy of nanoparticle delivery and represent a new paradigm for actively targeting and combating HCC. We comprehensively summarize the current understanding of these receptors, their role in nanoparticle targeting, and the impact of such targeted therapies on HCC. By gaining a deeper understanding of the receptor-mediated mechanisms of these innovative therapies, more effective and precise treatment of HCC can be achieved.

14

Marcelo, Gonçalo A., David Montpeyó, Joana Galhano, Ramón Martínez-Máñez, José Luis Capelo-Martínez, Julia Lorenzo, Carlos Lodeiro e Elisabete Oliveira. "Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer". International Journal of Molecular Sciences 24, n. 7 (1 aprile 2023): 6612. http://dx.doi.org/10.3390/ijms24076612.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles’ surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit® enteric coating and studied under extreme conditions.

15

Awad, Noor A., Nahi Y. Yassen, Amer T. Tawfeeq e Kismat M. Turki. "Hybrid nanoliposome as a targeted growth inhibitor for Cervical Carcinoma Cell line". Journal of the Faculty of Medicine Baghdad 57, n. 4 (3 gennaio 2016): 320–24. http://dx.doi.org/10.32007/jfacmedbagdad.574399.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background: targeted cancer nanotherapy represents a golden goal for nanobiotechnology to overcome the severe side effects of conventional chemotherapy. Hybrid nanoliposomes (HLs) composed of L-α-dimyristoylphosphatidylcholine (DMPC) and Polyoxyethylene (23) dodecyl ether (C12 (EO)23 ) can integrate selectively into the cancer cell membrane inducing cancer cell death.Objectives: to assess the capacity of locally (in hose) synthesized hybrid nanoliposome to inhibit the growth of cervix cancer cells (HeLa) and induce apoptosis.Patients and Methods: hybrid nanoliposomes(nHLs) synthesized by sonication method from a mixture of 90% mol DMPC and 10% mol C12(EO)23 in tissue culture media RPMI-1640 for 6 hours at 300W and 40ºC then filtration with 0.2μm filter. Shape and size characterized with scanning electron microscope (SEM). Viability of HeLa cell and normal lymphocytes challenged with HLs were determined using MTT assay. Induction of apoptosis in the challenged cells was examined by staining with fluorescence dye mix acridine orange/propidium iodide.Results: synthesized nHLs were in nanozise range and selectively inhibited HeLa cells proliferation with IC50 of 0.2mM DMPC with no effect against normal lymphocytes. Apoptosis was evident in 88.24% of HeLa cells population treated with HLs.Conclusion: synthesized nHLs may considered as promising nanotherapy, this study recommends further inspections for the mechanism of action of nHLs and their capabilities to inhibit other types of cancers both in vitro and in vivo

16

Asik, Elif, Yeliz Akpinar, Ayse Caner, Nermin Kahraman, Tulin Guray, Murvet Volkan, Constance Albarracin, Apar Pataer, Banu Arun e Bulent Ozpolat. "EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppressesBRCA1-mutated breast cancer". Nanomedicine 14, n. 17 (settembre 2019): 2315–38. http://dx.doi.org/10.2217/nnm-2019-0132.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Aim: To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods: We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results: Expression of EF2K is highly upregulated in the majority (78.5%) of BRCA1-mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. In vivo therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained EF2K gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. Conclusion: EF2K is a potential novel molecular target in BRCA1-mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K.

17

Zhou, Hui-fang, Happy W. Chan, Samuel A. Wickline, Gregory M. Lanza e Christine T. N. Pham. "α v β 3 –Targeted nanotherapy suppresses inflammatory arthritis in mice". FASEB Journal 23, n. 9 (17 aprile 2009): 2978–85. http://dx.doi.org/10.1096/fj.09-129874.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Journaux, Justine, M. Bejko, P. Clerc, Y. Al Yaman, C. Bousquet, S. Mornet, O. Sandre e V. Gigoux. "Nanotherapy of pancreatic adenocarcinoma by targeted magnetic hyperthermia: efficacy and mechanisms." Pancreatology 22 (novembre 2022): e74-e75. http://dx.doi.org/10.1016/j.pan.2022.06.193.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Haque, Sakib, Kiri Cook, Gaurav Sahay e Conroy Sun. "RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer". Pharmaceutics 13, n. 10 (15 ottobre 2021): 1694. http://dx.doi.org/10.3390/pharmaceutics13101694.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive cancer that has the highest mortality rate out of all breast cancer subtypes. Conventional clinical treatments targeting ER, PR, and HER2 receptors have been unsuccessful in the treatment of TNBC, which has led to various research efforts in developing new strategies to treat TNBC. Targeted molecular therapy of TNBC utilizes knowledge of key molecular signatures of TNBC that can be effectively modulated to produce a positive therapeutic response. Correspondingly, RNA-based therapeutics represent a novel tool in oncology with their ability to alter intrinsic cancer pathways that contribute to poor patient prognosis. Current RNA-based therapeutics exist as two major areas of investigation—RNA interference (RNAi) and RNA nanotherapy, where RNAi utilizes principles of gene silencing, and RNA nanotherapy utilizes RNA-derived nanoparticles to deliver chemotherapeutics to target cells. RNAi can be further classified as therapeutics utilizing either small interfering RNA (siRNA) or microRNA (miRNA). As the broader field of gene therapy has advanced significantly in recent years, so too have efforts in the development of effective RNA-based therapeutic strategies for treating aggressive cancers, including TNBC. This review will summarize key advances in targeted molecular therapy of TNBC, describing current trends in treatment using RNAi, combination therapies, and recent efforts in RNA immunotherapy, utilizing messenger RNA (mRNA) in the development of cancer vaccines.

20

Kara, Goknur, Pinar Atalay Dundar, Nermin Kahraman, Emir Baki Denkbas e Bulent Ozpolat. "Abstract 461: Dual-kinase targeted miRNA nanotherapy for the treatment of triple-negative breast cancer". Cancer Research 84, n. 6_Supplement (22 marzo 2024): 461. http://dx.doi.org/10.1158/1538-7445.am2024-461.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract Triple-negative breast cancer (TNBC) represents 20% of breast cancer (BC) patients (51,000 cases/year in the US). It is associated with a highly aggressive course, early metastasis and relapses, and drug-resistant phenotype. About 40% of the patients die within 5 years despite available therapies. If the disease is metastatic, patients survive only 13 months. Since TNBC does not express targetable receptors such as ER, PR, and HER2, and it is a highly heterogeneous cancer with six genetically defined sub-types, currently, there are no common actionable molecular targets and no effective targeted therapies for TNBC. microRNAs (miRNAs) are 18-20 nt long non-coding RNAs and are often dysregulated in cancer cells. Tumor-suppressive miRNAs specifically silence their protooncogenic target genes (mRNAs) by binding specifically to their 3’-UTRs located in their target mRNAs, leading to inhibition of oncogenes that play critical roles in cell proliferation, cell cycle, migration, invasion, angiogenesis, drug resistance, tumor growth, and progression. We have previously demonstrated that Eukaryotic Elongation factor-2 kinase (eEF2K) and AXL are oncogenic kinases, and their higher expression is associated with poor survival in patients with TNBC. However, currently, there is no FDA-approved eEF2K and AXL-targeted therapeutics. To effectively co-target these kinases, we extensively analyzed miRNA databases using miRNA target prediction algorithms and recently, we discovered that miR-329-3p has a specific binding site at both 3’-UTRs of eEF2K and AXL mRNAs. Analyzing the TCGA TNBC database, we found that low expression of miR-329-3p is correlated with shorter overall survival in TNBC patients, and the expression of miR-329-3p is commonly reduced or lost in TNBC patient tumors. Since the successful clinical application of miRNA-based therapeutics requires safe and effective nano-delivery systems, we have developed magnetic iron-oxide-based nanoparticles (MNPs) for the delivery of miR-329-3p. We showed that miR-329-3p significantly suppresses cell proliferation, invasion, and migration by targeting both eEF2K and AXL and their downstream mediators such as SRC/FAK and Cyclin D1 in TNBC cell lines. In vivo systemic treatment with MNPs-miR-329 completely blocks tumor growth in orthotopic MDA-MB-231 and MDA-MB-436 TNBC xenograft models in mice. Analysis of tumors shows remarkable inhibition in eEF2K and AXL expression, and clinically significant downstream targets including SRC, FAK, and Cyclin D1. We also demonstrated that miR-329 nanotherapy induces apoptosis and inhibits intratumoral proliferation in TNBC tumors in mice. Toxicity markers in mouse blood samples show that miR-329 nanotherapy is safe and not toxic to mice. Taken together, our study suggests that miR-329-3p nanotherapy may be used as a novel potential therapeutic approach in TNBC patients. Citation Format: Goknur Kara, Pinar Atalay Dundar, Nermin Kahraman, Emir Baki Denkbas, Bulent Ozpolat. Dual-kinase targeted miRNA nanotherapy for the treatment of triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 461.

21

Sajjadi, Mohaddeseh, Mahmoud Nasrollahzadeh, Babak Jaleh, Ghazaleh Jamalipour Soufi e Siavash Iravani. "Carbon-based nanomaterials for targeted cancer nanotherapy: recent trends and future prospects". Journal of Drug Targeting 29, n. 7 (18 febbraio 2021): 716–41. http://dx.doi.org/10.1080/1061186x.2021.1886301.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

KAJIMOTO, Kazuaki. "Adipose Vasculature Targeted Nanotherapy Leads to a Novel Strategy of Obesity Treatment". Oleoscience 15, n. 3 (2015): 107–14. http://dx.doi.org/10.5650/oleoscience.15.107.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Komizu, Yuji, Sayuri Nakata, Koichi Goto, Yoko Matsumoto e Ryuichi Ueoka. "Membrane-Targeted Nanotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis". ACS Medicinal Chemistry Letters 2, n. 4 (13 gennaio 2011): 275–79. http://dx.doi.org/10.1021/ml100269t.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Agrahari, Vivek. "The exciting potential of nanotherapy in brain-tumor targeted drug delivery approaches". Neural Regeneration Research 12, n. 2 (2017): 197. http://dx.doi.org/10.4103/1673-5374.200796.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Delie, Florence, Patrick Petignat e Marie Cohen. "GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78". Targeted Oncology 8, n. 4 (23 ottobre 2012): 225–30. http://dx.doi.org/10.1007/s11523-012-0234-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Nguyen, Dai Hai, Jung Seok Lee, Jin Woo Bae, Jong Hoon Choi, Yunki Lee, Joo Young Son e Ki Dong Park. "Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice". International Journal of Pharmaceutics 495, n. 1 (novembre 2015): 329–35. http://dx.doi.org/10.1016/j.ijpharm.2015.08.083.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Pan, Dipanjan, Benjamin Kim, Grace Hu, Deepti Sood Gupta, Angana Senpan, Xiaoxia Yang, Anne Schmieder et al. "A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy". Nanomedicine 10, n. 2 (gennaio 2015): 241–51. http://dx.doi.org/10.2217/nnm.14.101.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Ross, Michael H., Alison K. Esser, Gregory C. Fox, Anne H. Schmieder, Xiaoxia Yang, Grace Hu, Dipanjan Pan et al. "Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases". Cancer Research 77, n. 22 (30 agosto 2017): 6299–312. http://dx.doi.org/10.1158/0008-5472.can-17-1225.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

29

Wang, Xiaoxuan, Fangxuan Li, Jialu Zhang, Lu Guo, Mengmeng Shang, Xiao Sun, Shan Xiao et al. "A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy". Journal of Controlled Release 367 (marzo 2024): 45–60. http://dx.doi.org/10.1016/j.jconrel.2024.01.039.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

Zhang, Qixiong, Fuzhong Zhang, Shanshan Li, Renfeng Liu, Taotao Jin, Yin Dou, Zhenhua Zhou e Jianxiang Zhang. "A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment". Theranostics 9, n. 13 (2019): 3732–53. http://dx.doi.org/10.7150/thno.34377.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Puligujja, Pavan, Mariluz Araínga, Prasanta Dash, Diana Palandri, R. Lee Mosley, Santhi Gorantla, Larisa Poluektova, JoEllyn McMillan e Howard E. Gendelman. "Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice". Antiviral Research 120 (agosto 2015): 85–88. http://dx.doi.org/10.1016/j.antiviral.2015.05.009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Ng, Thomas S. C., David Wert, Hargun Sohi, Daniel Procissi, David Colcher, Andrew A. Raubitschek e Russell E. Jacobs. "Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101". Clinical Cancer Research 19, n. 9 (26 marzo 2013): 2518–27. http://dx.doi.org/10.1158/1078-0432.ccr-12-2738.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Song, Xinhao, Mengjuan Lin, Tian Fang, Jiahao Gong, Junqi Wang, Shasha Gao, Xiaolin Xu et al. "Maduramicin-guided nanotherapy: A polymeric micelles for targeted drug delivery in canine mammary tumors". Biomedicine & Pharmacotherapy 170 (gennaio 2024): 116062. http://dx.doi.org/10.1016/j.biopha.2023.116062.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Jiang, Quzi, Luodan Yu e Yu Chen. "Engineering Self-Assembled Nanomedicines Composed of Clinically Approved Medicines for Enhanced Tumor Nanotherapy". Nanomaterials 13, n. 18 (5 settembre 2023): 2499. http://dx.doi.org/10.3390/nano13182499.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The traditional nanocarriers are typically constructed to deliver anticancer agents for improving drug bioavailability and enhancing chemotherapeutic efficacy, but this strategy suffers from the critical issue of nanocarrier biosafety that hinders further clinical translation. In this work, a unique nanomedicine (PTX@ICG) has been rationally constructed by combining two clinically approved agents, i.e., paclitaxel (PTX) and indocyanine green (ICG), by a facile ultrasound-assisted self-assembly methodology. The formation of the nanostructure can effectively increase the enrichment of PTX and ICG molecules in the tumor site, and improve the utilization factor of hydrophobic PTX. Moreover, since the molecule interaction in PTX@ICG is mainly Van der Waals forces, the self-assembled structure can be spontaneously dissociated under laser irradiation and release PTX in situ to achieve safe tumor-targeted chemotherapy. Simultaneously, the released ICG can act as photothermic agents for photothermal therapy (PTT), thus combining chemotherapy and PTT to obtain an enhanced tumor nanotherapy via facile self-assembly. The synergistic chemo/photothermal tumor nanotherapy achieved the efficient tumor cell-killing effect and tumor-ablation ability, as systematically demonstrated both in vitro and in vivo. This work provides a distinct paradigm of the self-assembled nanomedicine design for effectively improving the drug bioavailability to achieve high antitumor efficacy.

35

Golzar, Hossein, Fatemeh Yazdian, Mohadeseh Hashemi, Meisam Omidi, Dorsa Mohammadrezaei, Hamid Rashedi, Masoumeh Farahani, Nazanin Ghasemi, Javad Shabani shayeh e Lobat Tayebi. "Optimizing the hybrid nanostructure of functionalized reduced graphene oxide/silver for highly efficient cancer nanotherapy". New Journal of Chemistry 42, n. 15 (2018): 13157–68. http://dx.doi.org/10.1039/c8nj01764f.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Janani, Balakarthikeyan, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi et al. "EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges". Vaccines 10, n. 4 (24 marzo 2022): 499. http://dx.doi.org/10.3390/vaccines10040499.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis—this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.

37

Lin, Mingzhen, Lili Teng, Yang Wang, Jiaxin Zhang e Xianglian Sun. "Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy". Drug Delivery 23, n. 4 (23 luglio 2015): 1420–25. http://dx.doi.org/10.3109/10717544.2015.1066902.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Khan, Suliman, Majid Sharifi, Jason P. Gleghorn, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Zehra Edis, Mohammadreza Amin et al. "Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy". Journal of Controlled Release 348 (agosto 2022): 127–47. http://dx.doi.org/10.1016/j.jconrel.2022.05.055.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Zhang, Jin. "The Application of Targeted Nanodrugs with Dual Responsiveness of PH and Ros in Preventing and Treating Vascular Restenosis". Journal of Healthcare Engineering 2021 (26 novembre 2021): 1–6. http://dx.doi.org/10.1155/2021/3982158.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

In order to study the application of PH- and Ros-responsive targeted nanodrugs in preventing and treating vascular restenosis, a method based on pH-responsive and reactive oxygen species- (ROS-) responsive carrier materials synthesized in the early stage and rapamycin as a model drug was proposed. This method evaluated the therapeutic advantages of PH and Ros dual-responsive nanoparticles and the effect of dual-responsive active targeted drug delivery nanoparticles on vascular restenosis in vivo by comparing with nonresponsive PH or Ros single responsive nanotherapy. By optimizing the feed mass ratio of pH-responsive materials (ACD) and ROS-responsive materials (OCD), the best pH and ROS responsive nanoparticles were prepared. It has been proved that nanoparticles have ultrasmall volume (10–1000 nm) and can easily pass through the blood vessel wall without causing damage and have the characteristics of targeting and sustained release, so they are an ideal carrier for local administration. Nanoparticles as gene vectors have also achieved good results.

40

Gupta, Tanvi, Tilahun Ayane Debele, Yu-Feng Wei, Anish Gupta, Mohd Murtaza e Wen-Pin Su. "Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence". Cancers 14, n. 1 (2 gennaio 2022): 213. http://dx.doi.org/10.3390/cancers14010213.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Since 2019, the SARS-CoV-2 pandemic has caused a huge chaos throughout the world and the major threat has been possessed by the immune-compromised individuals involving the cancer patients; their weakened immune response makes them vulnerable and susceptible to the virus. The oncologists as well as their patients are facing many problems for their treatment sessions as they need to postpone their surgery, chemotherapy, or radiotherapy. The approach that could be adopted especially for the cancer patients is the amalgamation of immunotherapy and nanotherapy which can reduce the burden on the healthcare at this peak time of the infection. There is also a need to predict or analyze the data of cancer patients who are at a severe risk of being exposed to an infection in order to reduce the mortality rate. The use of artificial intelligence (AI) could be incorporated where the real time data will be available to the physicians according to the different patient’s clinical characteristics and their past treatments. With this data, it will become easier for them to modify or replace the treatment to increase the efficacy against the infection. The combination of an immunotherapy and nanotherapy will be targeted to treat the cancer patients diagnosed with SARS-CoV-2 and the AI will act as icing on the cake to monitor, predict and analyze the data of the patients to improve the treatment regime for the most vulnerable patients.

41

Mitri, Fabio Franceschini. "Advances of the Nanotechnology in Targeted Nanomedicines for Treatment of Bone Cancers and Diseases". Journal of Cancer Research Updates 10 (30 dicembre 2021): 32–45. http://dx.doi.org/10.30683/1929-2279.2021.10.05.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The ever-evolving field of nanotechnology has been applied over the years as an amazing potential tool in bone disorders through the development of targeted drug nanosystems. Bone diseases can be referred as any bone condition able to cause morbidity or even mortality to the host. Osteosarcoma has been most investigated condition for management and treatment by nanomedicine, and several nanomaterials such as nanoparticles, nanocapsules, nanospheres, nanodiamonds are being used for drug delivery. Likewise, other bone diseases, such as osteoporosis, osteonecrosis, osteoarthritis, bone tuberculosis have received nanotherapy with a large rate of success. The nanomedicine seems to make up a targeting lack by conventional therapy and chemotherapy, besides appointing to a trend of conservative clinical treatment, especially for severe disorders. Additionally, nanomedicine has advanced over the years, therefore, there is a strong need to accelerate its application in bone diseases reducing the mortality rate related to these conditions. This review article provides an overview on the advances of nanotechnology over the last two decades and highlights the pathways of investigations for targeted delivery nanoensembles.

42

Wu, Jianrong, Zheying Meng, Agata A. Exner, Xiaojun Cai, Xue Xie, Bing Hu, Yu Chen e Yuanyi Zheng. "Biodegradable cascade nanocatalysts enable tumor-microenvironment remodeling for controllable CO release and targeted/synergistic cancer nanotherapy". Biomaterials 276 (settembre 2021): 121001. http://dx.doi.org/10.1016/j.biomaterials.2021.121001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Yoo, Byunghee, Amol Kavishwar, Alana Ross, Ping Wang, Doris P. Tabassum, Kornelia Polyak, Natalia Barteneva et al. "Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer". Cancer Research 75, n. 20 (10 settembre 2015): 4407–15. http://dx.doi.org/10.1158/0008-5472.can-15-0888.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

Bariana, Manpreet, Beilu Zhang, Jingyu Sun, Elena Cassella, Janice Rateshwar, Ming Tony Tan, Weiwei Wang et al. "Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor". Blood 140, Supplement 1 (15 novembre 2022): 6018–19. http://dx.doi.org/10.1182/blood-2022-160324.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Trandafir, Laura M., Gianina Dodi, Otilia Frasinariu, Alina C. Luca, Lacramioara I. Butnariu, Elena Tarca e Stefana M. Moisa. "Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective". Nutrients 14, n. 18 (13 settembre 2022): 3774. http://dx.doi.org/10.3390/nu14183774.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic side effects. Therefore, novel solutions for tackling obesity-associated diseases and providing insights into the development of innovative or improved therapies are necessary. Targeted nanotherapy is a revolutionary technology, offering a promising solution for combatting the disadvantages of currently available therapies for treating obesity and dyslipidemia due to its superior features, which include specific cell targeting, the protection of drugs against physiological degradation, and sustained drug release. This review presents a brief assessment of obesity and dyslipidemia, their impacts on human health, current treatment, and limitations, and the role and potential use of nanotechnology coupled with targeted drug delivery and nutraceuticals as emerging therapies. To the best of our knowledge, this paper presents, for the first time in the literature, a comparison between obesity and dyslipidemia nano-formulations based on drugs and/or natural extracts applied in experimental studies.

46

Reddy, Hrushikesh, G. Jyothi, Maheshwari, D.Prasad e M.Sudhakar. "Nanoliposomes-A Review". World Journal of Pharmaceutical Sciences 10, n. 03 (2022): 299–307. http://dx.doi.org/10.54037/wjps.2022.100308.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Nanoliposome, or submicron bilayer lipid vesicle, is a new technology for the encapsulation and delivery of bioactive agents. The list of bioactive material that can be incorporated tonanoliposomes is huge, ranging from pharmaceuticals to cosmetics and nutraceuticals. Nanoliposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life and reducing toxicity. The sole characteristic of nanoliposomes is their ability to compartmentalize and solubilize both hydrophilic and hydrophobic materials. This sole characteristic, coupled with biocompatibility and biodegradability make nanoliposomes very attractive as drug delivery vehicles. This review article intends to provide an overview of liposomes and nanoliposomes their properties, preparation methods and evaluation parameters. Also it explains various applications of nanoliposomes in nanotherapy including diagnostics, targeted cancer, gene therapy, cosmetics and nutraceuticals.

47

SILVA, ADRIANA L. DA, RAQUEL S. SANTOS, DÉBORA G. XISTO, SILVIA DEL V. ALONSO, MARCELO M. MORALES e PATRICIA R. M. ROCCO. "Nanoparticle-based therapy for respiratory diseases". Anais da Academia Brasileira de Ciências 85, n. 1 (5 marzo 2013): 137–46. http://dx.doi.org/10.1590/s0001-37652013005000018.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Nanotechnology is an emerging science with the potential to create new materials and strategies involving manipulation of matter at the nanometer scale (<100 nm). With size-dependent properties, nanoparticles have introduced a new paradigm in pharmacotherapy – the possibility of cell-targeted drug delivery with minimal systemic side effects and toxicity. The present review provides a summary of published findings, especially regarding to nanoparticle formulations for lung diseases. The available data have shown some benefits with nanoparticle-based therapy in the development of the disease and lung remodeling in respiratory diseases. However, there is a wide gap between the concepts of nanomedicine and the published experimental data and clinical reality. In addition, studies are still required to determine the potential of nanotherapy and the systemic toxicity of nanomaterials for future human use.

48

Mahajan, Supriya, Ravikumar Aalinkeel, Jessica Reynolds, Bindukumar Nair, Donald Sykes, Wing-Cheung Law, Paras Prasad e Stanley Schwartz. "Innovative nanotherapy for the treatment of the chronic skin condition, rosacea. (P3259)". Journal of Immunology 190, n. 1_Supplement (1 maggio 2013): 192.15. http://dx.doi.org/10.4049/jimmunol.190.supp.192.15.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract A chronic skin disorder called Rosacea is primarily characterized by inflammation associated with abnormal innate immune response and the current treatments include oral and topical antibiotics and antimicrobials. CD163 plays a key role in etiology of Rosacea and a combination targeted nanotherapy which includes an topical antibiotic such as doxycycline, an anti-microbial such as Azelaic acid and the anti CD163 antibody would be an effective therapy for Rosacea. We developed a nanoemulsion for the treatment of Rosacea using fluorophores called nanophosphors which are upconversion nanoparticles (UCNPs), that have the ability to convert near infrared radiations with lower energy into visible radiations with higher energy via a nonlinear optical process and exhibit unique luminescent properties, including high penetration depth into tissues. Our goal was to evaluate the transdermal delivery of this nanoemulsion using an in-vitro skin barrier model (EpiDerm™). Dermal permeability coefficient is calculated and drug concentrations are determined by HPLC. Our results show a significantly higher 72% increase (p<0.01) in uptake of this nanoemulsion by dermal keratinocytes and fibroblasts and deeper penetration into the skin layers as compared to topical application of the antibiotic and/or antimicrobial alone. Although, this nanoformulation is specific to the treatment of Rosacea, this nano-therapeutic approach can be applied to other skin disorders.

49

Newton, Emily R., David C. Gillis, Kui Sun, Brooke R. Dandurand, Robin Siletzky, Suvendu Biswas, Mark R. Karver, Nick D. Tsihlis, Samuel I. Stupp e Melina R. Kibbe. "Evaluation of a Targeted Drug‐Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model". Advanced NanoBiomed Research 1, n. 7 (3 maggio 2021): 2000093. http://dx.doi.org/10.1002/anbr.202000093.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Halling Folkmar Andersen, Anna, e Martin Tolstrup. "The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection". Viruses 12, n. 4 (7 aprile 2020): 412. http://dx.doi.org/10.3390/v12040412.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Oral administration of a combination of two or three antiretroviral drugs (cART) has transformed HIV from a life-threatening disease to a manageable infection. However, as the discontinuation of therapy leads to virus rebound in plasma within weeks, it is evident that, despite daily pill intake, the treatment is unable to clear the infection from the body. Furthermore, as cART drugs exhibit a much lower concentration in key HIV residual tissues, such as the brain and lymph nodes, there is a rationale for the development of drugs with enhanced tissue penetration. In addition, the treatment, with combinations of multiple different antiviral drugs that display different pharmacokinetic profiles, requires a strict dosing regimen to avoid the emergence of drug-resistant viral strains. An intriguing opportunity lies within the development of long-acting, synthetic scaffolds for delivering cART. These scaffolds can be designed with the goal to reduce the frequency of dosing and furthermore, hold the possibility of potential targeting to key HIV residual sites. Moreover, the synthesis of combinations of therapy as one molecule could unify the pharmacokinetic profiles of different antiviral drugs, thereby eliminating the consequences of sub-therapeutic concentrations. This review discusses the recent progress in the development of long-acting and tissue-targeted therapies against HIV for the delivery of direct antivirals, and examines how such developments fit in the context of exploring HIV cure strategies.

Articoli di riviste sul tema "Targeted nanotherapy"

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili